Study of Low-dose Interleukin-2 Effects on Tissue-resident Regulatory T Cells in Adults Undergoing Heart Bypass Surgery After a Heart Attack

What this Trial Is About

Researchers are investigating the effects of low-dose interleukin-2 ld-IL-2 treatment on tissue-resident regulatory T cells Tregs in patients who have had a myocardial infarction heart attack. The study aims to compare the gene signatures related to activation, proliferation, and suppressive function of these Tregs in heart-related tissues versus peripheral blood, to better understand ld-IL-2s impact on tissue repair and inflammation after heart damage. This research focuses on patients undergoing coronary artery bypass graft CABG surgery and seeks to improve insights into immune responses in damaged heart tissues. Participants receive either ld-IL-2 at doses of 1.5 million international units MIU or 2.0 MIU daily for 5 consecutive days, followed by weekly doses if needed until their CABG surgery is completed. A control group receives standard care treatment without ld-IL-2. The ld-IL-2 is administered subcutaneously, and the study compares outcomes across these different treatment groups to assess the effects on immune cells within heart tissues and blood. Throughout the study, samples from heart tissues and peripheral blood are collected during surgery to analyze Treg gene signatures and other immune cell differences using advanced RNA sequencing methods. Researchers measure how ld-IL-2 influences immune cells related to tissue repair and anti-inflammatory responses. The study monitors participants from treatment through surgery and evaluates both primary and secondary immune-related outcomes to understand the therapys impact on heart tissue healing and immune function.

Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells